LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.

Nearly a year after Labcorp struck a deal for certain diagnostics assets from BioReference Health, the lab-testing giant is back to buy the firm’s cancer tests. Labcorp is paying $192.5 million ...

Nearly a year after Labcorp struck a deal for certain diagnostics assets from BioReference Health, the lab-testing giant is ...

Labcorp has entered into an agreement to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO ...

Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth ...

The independent laboratory company has entered an agreement to acquire BioReference Health's oncology diagnostic services.

The deal is part of BioReference's ongoing effort to streamline its business to achieve profitability and follows the sale last year of clinical laboratory assets to Labcorp.

Labcorp Holdings has signed a deal to buy certain assets of OPKO Health's BioReference Health unit for up to $225 million. Labcorp on Tuesday said it will pay $192.5 million at closing for ...

OPKO Health (NASDAQ: OPK) has recently received a number of price target changes and ratings updates: 3/19/2025 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now ...

Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services Through this transaction, Labcorp will acquire BioReference Health's ...